News

Coya Therapeutics is expanding the pipeline for its COYA 302 immunotherapy, adding two neurodegenerative disorders — frontotemporal dementia (FTD) and Parkinson’s disease — as targets for the amyotrophic lateral sclerosis (ALS) treatment candidate. Brain inflammation is known to drive Parkinson’s — and is a mechanism shared…

The RAZ Memory Cell Phone will allow people with impaired speech, including those with Parkinson’s disease, to speak using their own voice during video phone calls and be fully understood. The speech recognition technology was developed by Voiceitt, a voice AI and machine learning company, in partnership…

A new test that can detect extremely small concentrations of clumped alpha-synuclein may help to detect Parkinson’s disease and related disorders in early stages. The test, reportedly able to spot single protein fibrils, was described in the study, “Toward the quantification of [alpha]-synuclein aggregates with digital…

Phosphorylated alpha-synuclein, a modified form of the protein that forms toxic clumps in the brains of people with Parkinson’s disease and related disorders, appears to play an important role in the normal function of nerve cells, a study shows. When it’s modified, alpha-synuclein binds…

A new brain imaging method may help diagnose mild traumatic brain injury (mTBI), which according to some studies can be associated with a 50% higher risk of developing Parkinson’s. Available methods, like magnetic resonance imaging (MRI), leave most cases of mTBI, or concussions, undiagnosed. They occur when a physical…

Scientists have developed a molecule that promotes the clearance of toxic clumps of the alpha-synuclein protein — a hallmark of Parkinson’s disease — by targeting its template rather that the protein itself. “We have found that targeting the RNA needed to build the toxic protein may be an optimal…

Produodopa (foslevodopa/foscarbidopa), AbbVie‘s continuous under-the-skin (subcutaneous) infusion formulation of levodopa/carbidopa, now is available in the European Union (EU) for advanced Parkinson’s disease patients whose severe motor fluctuations and involuntary movements are not controlled well with standard therapies. AbbVie initially was granted marketing authorization for Produodopa — also known…

The U.S. Food and Drug Administration (FDA) has approved Medtronic‘s Percept RC deep brain stimulation (DBS) system, clearing it for use to treat Parkinson’s disease and other movement disorders. DBS is a surgical procedure in which an electrode is implanted in the brain to provide electrical stimulation…

Scientists have created an implantable device that can provide electrical stimulation in the body without need for a battery. The new technology, which is powered by ultrasound, may serve as a useful platform to develop next-generation implantable devices to treat conditions such as Parkinson’s disease. The team described its…

People who carry a specific mutation in the gene for a small protein called SHLP2 are about half as likely to develop Parkinson’s disease, a study from the University of Southern California (USC) has found, offering a new direction to treat the disease. The mutation, found mainly in people…